CAS 1394076-92-6

5-(6-(3-Methoxyoxetan-3-yl)-4-Morpholinothieno[3,2-d]pyriMidin-2-yl)pyriMidin-2-aMine

Description:

The chemical substance known as 5-(6-(3-Methoxyoxetan-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine, with the CAS number 1394076-92-6, is a complex organic compound characterized by its multi-cyclic structure, which includes pyrimidine and thieno moieties. This compound features a morpholine ring, contributing to its potential biological activity, and an oxetane group, which may influence its chemical reactivity and stability. The presence of a methoxy group suggests possible interactions with biological targets, enhancing its solubility and lipophilicity. Such compounds are often investigated for their pharmacological properties, particularly in the context of medicinal chemistry, where they may exhibit activity against specific diseases or conditions. The intricate arrangement of functional groups and rings in this molecule can lead to diverse interactions with biological systems, making it a candidate for further research in drug development. However, detailed studies on its pharmacodynamics, pharmacokinetics, and toxicity would be necessary to fully understand its potential applications.

5-[6-(3-Methoxy-3-oxetanyl)-7-methyl-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-2-pyrimidinamine

CAS: 1394076-92-6

Formula: C₁₉H₂₂N₆O₃S

Purity: 98%

Color and Shape: Solid

Molecular weight: 414.4814

Ref: IN-DA009CI2

GNE-317

CAS: 1394076-92-6

GNE-317

Purity: ≥98%

Molecular weight: 414.48g/mol

Ref: 54-BUP12450

GNE-317

CAS: 1394076-92-6

GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).

Formula: C₁₉H₂₂N₆O₃S

Purity: 98.42% - 99.54%

Color and Shape: Solid

Molecular weight: 414.48

Ref: TM-T6845

GNE-317

CAS: 1394076-92-6

GNE-317 is a cancer therapeutic that inhibits the activity of CDK4/6 and is currently in phase II clinical trials. GNE-317 has been shown to be effective in inhibiting tumor growth in mice with metastatic melanoma. The mechanism of action of GNE-317 is by binding to CDK4/6 and inhibiting their activity, which prevents phosphorylation of effector proteins such as S6 kinase. This inhibition leads to a decrease in cell proliferation and an increase in apoptosis.
GNE-317 has been shown to inhibit the growth of human breast cancer cells without affecting normal cells. It also inhibits Hdac, a protein involved in cell signaling pathways that can lead to uncontrolled cell growth, which may be due to its ability to inhibit histone deacetylation.

Formula: C₁₉H₂₂N₆O₃S

Purity: Min. 95%

Molecular weight: 414.48 g/mol

Ref: 3D-UFC07692